The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

March 16, 2024

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

March 16, 2024

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

March 10, 2024

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

March 10, 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

March 08, 2024

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

March 05, 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

March 05, 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

March 04, 2024

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

February 29, 2024

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

February 26, 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

February 24, 2024

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

February 23, 2024

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

February 22, 2024

Dr Tripathy discusses the unique aspects of the Miami Breast Cancer Conference that make it worth returning to year after year.

February 21, 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

February 19, 2024

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

February 19, 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

February 19, 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

February 12, 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

February 12, 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

February 05, 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.